Mental state · schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
Quetiapine showed no clear difference in global state No clinical significant response as defined by the… compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · patients with schizophrenia
1 finding from 1 review
Cognitive function · patients with schizophrenia
1 finding from 1 review
Adverse effects: unspecified extrapyramidal symptoms · patients with schizophrenia
Quetiapine probably leads to lower extrapyramidal effects compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Prolactin level Average level in ng/mL · patients with schizophrenia
1 finding from 1 review
Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Sexual function: Subjective assessment (prolactin levels, ng/ml) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE (very low certainty).
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Psychopathology (PANSS) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… showed no clear difference in dropouts ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… probably leads to higher response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… probably leads to higher remission (MADRS score ≤ 8/HAM‐D score ≤ 7) ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review